Physician profile
Eric Meyers
NPI 1942730916
$2,966.07
in general payments reported to CMS, 2019-2025
21 companies · $1,138 in 2025
The $1,138 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $99.00 · 2021: $381 · 2022: $332 · 2023: $311 · 2024: $705 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433 · Consulting Fee: $645 · Education: $75.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.44 |
| Consulting Fee | $645.00 |
| Education | $75.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $991.21 | 2020-2025 | Monjuvi, Pemazyre |
| Beigene USA, INC. | $416.19 | 2021-2023 | Brukinsa |
| Inari Medical, INC. | $183.00 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Celgene Corporation | $177.34 | 2024-2025 | Reblozyl, Opdivo |
| Janssen Biotech, INC. | $160.03 | 2023-2024 | Akeega, Erleada, Tecvayli |
| Glaxosmithkline, LLC. | $142.47 | 2025 | Jemperli, Ojjaara, Blenrep |
| Genentech USA, INC. | $137.85 | 2021 | |
| Genzyme Corporation | $118.47 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $110.02 | 2024 | Calquence, Lynparza |
| Penumbra, INC. | $109.22 | 2024 | Indigo System |
| Jazz Pharmaceuticals INC. | $103.35 | 2024-2025 | |
| Lilly USA, LLC | $84.47 | 2022 | |
| Janssen Pharmaceuticals, INC | $58.32 | 2024 | Xarelto, Rybrevant |
| Aveo Pharmaceuticals, INC. | $33.40 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $29.98 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $24.19 | 2024 | |
| Agios Pharmaceuticals, INC. | $21.68 | 2025 | Pyrukynd |
| Bayer Healthcare Pharmaceuticals INC. | $18.31 | 2025 | |
| Sumitomo Pharma America, INC. | $17.28 | 2024 | Orgovyx |
| Novartis Pharmaceuticals Corporation | $16.87 | 2024 | |
| Gilead Sciences, INC. | $12.42 | 2025 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Meyers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.